Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, 434000, Hubei, China.
Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, 434000, Hubei, China.
Biomark Med. 2024;18(6):221-230. doi: 10.2217/bmm-2023-0591. Epub 2024 Apr 17.
This study intended to explore the relationship of PLK3 with prognosis in patients with colorectal cancer (CRC). PLK3 positivity was detected by immunohistochemistry in 160 patients with CRC receiving surgical resection. The median tumor PLK3-positive rate was 26.5%. Tumor PLK3-positive rate was related to increased lymph node stage (p = 0.002) and tumor-node-metastasis stage (p < 0.001) of CRC. Tumor PLK3-positive rate ≥30% was related to shortened disease-free survival (p = 0.009) and overall survival (p = 0.003); tumor PLK3-positive rate ≥50% showed a stronger correlation with them (both p = 0.001), which was validated by multivariate Cox regression analyses (both p < 0.05). Tumor PLK3-positive rate ≥50% relates to increased tumor stage and unfavorable survival in patients with CRC.
本研究旨在探讨 PLK3 与结直肠癌（CRC）患者预后的关系。对 160 例接受手术切除的 CRC 患者进行免疫组织化学检测 PLK3 阳性，中位肿瘤 PLK3 阳性率为 26.5%。CRC 的肿瘤 PLK3 阳性率与淋巴结分期增加（p=0.002）和肿瘤-淋巴结-转移分期（p<0.001）有关。肿瘤 PLK3 阳性率≥30%与无病生存（p=0.009）和总生存（p=0.003）缩短有关；肿瘤 PLK3 阳性率≥50%与它们的相关性更强（均 p=0.001），这也通过多变量 Cox 回归分析得到了验证（均 p<0.05）。肿瘤 PLK3 阳性率≥50%与 CRC 患者肿瘤分期增加和生存不良有关。
